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H I G H L I G H T S
 The Canadian Health Measures Survey (CHMS) has been collecting biomonitoring data from the general Canadian population since 2007 and has
provided, to date, nationally representative baseline concentrations for hundreds of environmental biomarkers in blood and/or urine.
 A number of screening values have been developed as tools to interpret biomonitoring data in a human health risk assessment context. These values
include Biomonitoring Equivalents (BEs) derived from existing exposure guidance values.
 BEs have been derived for a number of biomarkers of exposure measured in the CHMS and were compared to biomonitoring data from the CHMS to
calculate hazard quotient (HQ).
 Results suggest most chemical exposures in Canadians seem below current exposure guidance values. However, inorganic arsenic and cadmium
exposure may be exceeding risk assessment-based exposure guidance values, in portions of the Canadian population at least intermittently.
 This type of analysis may contribute to screening and prioritization efforts.
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A B S T R A C T
Since 2007, the Canadian Health Measures Survey (CHMS) has been collecting biomonitoring data from
the general Canadian population and has provided, to date, nationally representative concentrations for
hundreds of environmental biomarkers in blood or urine. Biomonitoring Equivalents (BEs) have been
developed as tools to help interpret biomonitoring data in a health risk context at a population level. In
this paper, BEs are used to relate biomonitoring data from the CHMS (2007–2011) to existing exposure
guidance values developed by Health Canada and other government agencies. Chemical-speciﬁc hazard
quotients (HQs) and/or cancer risk estimates are calculated using existing BEs corresponding to
environmental chemicals analyzed in the CHMS.
For the majority of environmental chemicals, calculated HQ values are less than 1 indicating exposure
is below published exposure guidance values. Individual biomonitoring data for two biomarkers of metal
exposure (inorganic arsenic and cadmium) resulted in HQ values exceeding 1 suggesting that exposure
may be above existing guidance values for a portion of the population, at least intermittently. This type of
analysis may be used by researchers, risk assessors, and risk managers in prioritization efforts.
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nc-nd/3.0/).1. Introduction
The Canadian Health Measures Survey (CHMS) is the most
comprehensive and nationally representative survey that provides
information on the general health and lifestyles of Canadians
including weight, height, physical ﬁtness, and chronic and
infectious disease, and on the concentrations of environmental
chemicals and/or their metabolites in blood and urine as
biomarkers of exposure (Health Canada, 2010c, 2013b). Biomarkersess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
A. St-Amand et al. / Toxicology Letters 231 (2014) 126–134 127of exposure are deﬁned as a chemical, its metabolite, or the
product of an interaction between a chemical and some target
molecule or cell that is measured in the human body (NRC, 2006).
The latest biomonitoring report released by Health Canada
provides population-level data for 91 biomarkers of exposure in
Canadians aged 3–79 years collected from 2009 to 2011 (Health
Canada, 2013b). Previously, from 2007 and 2009 the CHMS
reported on 81 biomarkers of exposure in Canadians aged 6–79
years (Health Canada, 2010c). Additionally, pooled serum samples
from CHMS (2007–2009) analyzed for additional persistent
organic pollutants (POPs) include data on exposure to polychlori-
nated biphenyls (PCBs), dioxins, and furans (Rawn et al., 2012,
2013). The pooled study provides national estimates for POPs
concentrations in the human serum of Canadians by pooling the
small volumes of left over serum samples from CHMS cycle
1 collection (2007–2009).
Although, our ability to measure increasing number of
chemicals at lower detection levels has improved, our interpreta-
tion of associated risks to human health is still limited (Haines
et al., 2011). Health-based tissue guidelines or intervention levels
are derived on the basis of toxicological and epidemiological
studies and can be used to compare with biomarker concentrations
to determine if levels are associated with potentially increased
health risk. In Canada, and elsewhere only a few substances,
including lead and mercury, have intervention levels based upon
direct, quantitative relationships between biomarker measure-
ments and health effects (CEOH, 1994; Legrand et al., 2010). Such
risk assessment values come from time- and resource-intensive
epidemiological studies. Data from the CHMS show that the
majority of Canadians have, lead, and mercury levels below their
respective provisional Canadian blood guidance values (Health
Canada, 2013a; Lye et al., 2013). For other biomarkers measured in
the CHMS, Biomonitoring Equivalents (BEs) can be used as tools to
help interpret biomonitoring data in a health risk context at a
population level. A BE is deﬁned as an estimated concentration of
an environmental chemical in humans consistent with an existing
non-cancer health-based exposure guidance value, such as a
tolerable daily intake (TDI) or with an exposure guidance value
based on cancer endpoints, such as a risk-speciﬁc dose (RSD) (Hays
et al., 2008a). In this paper, existing BEs are used to screen
biomonitoring data from the CHMS (2007–2011) and provide an
assessment of which biomarkers are present at concentrations
below, near, or above existing exposure guidance values. This
evaluation may help to set priorities for future research,
monitoring, and surveillance activities and for potential risk
assessment or risk management follow-up efforts.
2. Methods
2.1. Canadian Health Measure Survey biomonitoring data
The CHMS is representative of the general Canadian population
aged 6–79 years and 3–79 years for the data collected in 2007–
2009 and 2009–2011, respectively (Tremblay et al., 2007; Giroux
et al., 2013). For biomarkers analyzed in 2007–2009, including
DDT, HCB, PBDE, and PCBs, the sample population comprised
approximately 1666 individuals between the ages of 20 and 79
years. The pooled biomarkers from 2007–2009 (i.e., dioxins and
HBCD) were analyzed in a total sample population comprising
5059 individuals between the ages of 6 and 79 years divided over
59 composite pools. The remaining biomarkers were analyzed in
2009–2011 in a sub-sample population of approximately 2000 in-
dividuals except for cadmium which was measured in the full
sample population of 5059 individuals aged 6–79 years. In order to
be representative of the Canadian population, the analyses were
weighted using the CHMS survey weights (Statistics Canada, 2011,2013). The data were analyzed with SAS 9.2 (SAS Institute Inc., U.S.)
and SUDAAN 10.0.1 software (RTI International, U.S.). This analysis
is provided for a subset of the CHMS environmental chemicals for
which BEs were available (Table 1).
For each biomarker or sum of biomarkers, descriptive statistics
(geometric means and selected percentiles with their associated
95% conﬁdence intervals) were calculated on the volumetric
(units of micrograms per liter urine or whole blood) or lipid-
adjusted (units of nanogram per gram plasma lipids) concen-
trations. For arsenic, dichlorodiphenyltrichloroethane (DDT), di-2
(ethylhexyl) phthalate (DEHP), hexabromocyclododecane
(HBCD), and polychlorinated biphenyls (PCBs), descriptive
statistics were calculated based upon the sum of the appropriate
biomarkers according to the requirements of the screening values
(ANSES, 2010; Aylward and Hays, 2011; Aylward et al., 2009b;
Hays et al., 2010). Biomarker concentrations below the limit of
detection (LOD) were assigned a value of LOD/2, except for
concentrations of DDT biomarkers below the LOD which were
assigned a value of zero to avoid overestimation as DDT was
detected in only a small portion of the population (Statistics
Canada, 2011, 2013). Pooled biomonitoring data for HBCD,
polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated
dibenzofurans (PCDFs), and dioxin-like PCBs (DL-PCBs) were
obtained from Rawn et al. (2012, 2013).
Sub-population analyses by age, sex, or smoking status were
only conducted where relevance was suggested by existing
information. In the case of cadmium, smoking has been identiﬁed
as a major source of exposure (Environment Canada, 1994; Health
Canada, 1994a; IARC, 2012) and therefore, descriptive statistics for
cadmium in sub-populations of smokers and non-smokers were
calculated. Smoking status was deﬁned in terms of urinary cotinine
concentrations, with smokers deﬁned as those with concentra-
tions exceeding 50 ng/ml, as recommended by the Society for
Research on Nicotine and Tobacco (SRNT Subcommittee on
Biochemical Veriﬁcation 2002). No attempt was made to
comprehensively assess trends with smoking, sex, or age across
all the chemicals in the analyses.
2.2. Biomonitoring Equivalents
BEs are based on exposure guidance values established by
government agencies, such as Health Canada, the United States
Environmental Protection Agency (U.S. EPA), or the World Health
Organization (WHO) (Hays et al., 2007, 2008a). Biomarkers
selected for this analysis are presented in Table 1. BE values based
upon risk speciﬁc doses from cancer risk assessments (i.e., BERSD)
were available for three biomarkers: arsenic, DDT, and hexachlor-
obenzene (HCB) and are presented in Table 5 (Aylward et al., 2010;
Hays et al., 2010; Kirman et al., 2011).
The methods for deriving BEs are reviewed in Angerer et al.
(2011). For interpreting CHMS biomarkers, BE values based on
Health Canada exposure guidance values were favored. When
these values were not available, BEs based on risk assessment
values from U.S. EPA or other international health organizations
were selected. A provisional BE value was identiﬁed for HBCD
(Aylward and Hays, 2011). Provisional values are derived based on
the point of departure from Health Canada screening and risk
assessments in the absence of established exposure guidance
values. A concentration of concern was identiﬁed for PCBs (ANSES,
2010).
2.3. Risk-based approach: screening with Biomonitoring Equivalents
For non-cancer endpoints, hazard quotients (HQ) were calcu-
lated as the ratio of the biomarker concentration to the chemical-
speciﬁc BE value:
Table 1
Environmental chemicals and their respective biomarkers from the Canadian Health Measures Survey for which existing Biomonitoring Equivalents were identiﬁed.
Environmental chemicals Biomarkers (if different) Relevance of biomarkera References
Concentration of concern
PCBs PCB 138, PCB 153, PCB 180 – ANSES, 2010
Biomonitoring Equivalents
2,4-D Medium Aylward and Hays, 2008
Arsenic, inorganic DMA, MMA Low Hays et al., 2010
BBP MBzP Medium Aylward et al., 2009a
Bisphenol A Low Krishnan et al., 2010
Cadmium High Hays et al., 2008b
Cyﬂuthrin 4-F-3-PBA Low to medium Hays et al., 2009
DnBP MnBP Medium Aylward et al., 2009a
DDT DDT, DDE High Kirman et al., 2011
DEHP MEHP, MEOHP, MEHHP Medium Aylward et al., 2009b
Deltamethrin cis-DBCA Low Aylward et al., 2011
DEP MEP Medium Aylward et al., 2009a
Dioxins 7 PCDD, 10 PCDF,12 DL-PCBs High Aylward et al., 2008, 2012
Hexachlorobenzene High Aylward et al., 2010
PBDE 99 Low to medium Krishnan et al., 2011
Triclosan Low Krishnan et al., 2010
Provisional Biomonitoring Equivalent
HBCD a-HBCD, b-HBCD,g-HBCD – Aylward and Hays, 2011
Abbreviations: BBP, benzyl butyl phthalate; 2,4-D, 2,4-dichlorophenoxyacetic acid; cis-DBCA,cis-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane-1-carboxylic acid; DnBP,
di-n-butyl phthalate; DDE, dichlorodiphenyldichloroethylene; DDT, dichlorodiphenyltrichloroethane; DEHP, di-2(ethylhexylphthalate); DEP, diethyl phthalate; DL-PCB,
dioxin-like polychlorinated biphenyls; DMA, dimethylarsinic acid; 4-F-3-PBA, 4-ﬂuoro-3-phenoxybenzoic acid; HBCD, hexabromocyclododecane; MnBP,mono-n-butyl
phthalate; MBzP, mono-benzyl phthalate; MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEHP, mono-2-ethylhexyl phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl)
phthalate; MEP, mono-ethyl phthalate; MMA, monomethylarsonic acid; PBDE, polybrominateddiphenyl ether; PCB, polychlorinated biphenyl; PCDD, polychlorinated
dibenzodioxins; PCDF, polychlorinated dibenzofurans.
a As determined during the derivation of the Biomonitoring Equivalent based upon the degree of conﬁdence in the relationship between the biomarker and the critical dose
metric (see reference for detailed information).
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HQs were calculated for biomarker concentration at the
population geometric mean (GM) and upper bound (95th
percentile or maximum value), as appropriate for each environ-
mental chemical. Since BEs are based on RfD or TDI values, HQs
near or exceeding a value of 1 provide an indication that exposure
levels are near or exceeding the existing exposure guidance values.
For carcinogens such as inorganic arsenic, DDT and HCB, risk-
speciﬁc doses (RSD) have been calculated for a range of risk levels
of interest from 1 in 10,000 (1 104) to 1 in 1,000,000 (1 106).
BERSD provide an estimate of the steady-state concentrations that
would result from chronic exposure, over a lifetime, at the RSDs
(Aylward et al., 2013). In this evaluation, cancer risks correspond-
ing to 5th, 25th, 75th, and 95th percentile were estimated with
information provided in chemical speciﬁc BE derivation, and
assuming linear extrapolation (Aylward et al., 2010; Hays et al.,
2010; Kirman et al., 2011).
3. Results
Descriptive statistics for individual and summed biomarkers of
exposure for environmental chemicals included in the CHMS are
summarized alongside their respective BE values in Tables 2–4.
Environmental chemicals were divided into two groups based
upon estimated half-lives. Table 2 contains chemicals with short
estimated half-lives of elimination (<1 day) including inorganic
arsenic, phthalates, environmental phenols and pesticides. Con-
centrations of persistent environmental chemicals including
cadmium, DDT, HCB, PCBs, polybrominated diphenyl ether (PBDE),
HBCD and PCDD/F + DL-PBCs are presented in Tables 3 and 4.
The HQ values for the population geometric means and 95th
percentile for biomarkers of inorganic arsenic, phthalates,pesticides, and environmental phenols are presented in Fig. 1.
These chemicals have short estimated half-lives of elimination
relative to expected exposure frequencies; for example, biomark-
ers of inorganic arsenic have estimated half-lives of 4–28 h (Hays
et al., 2010). When the biomarker’s half-life in urine is short, large
variations may be expected in urine concentrations from an
individual over the course of a single day (Aylward et al., 2012). For
these short-lived chemicals, biomarker concentrations at the tails
of the distributions (e.g., 95th percentile) may not be very
indicative of long-term exposure levels. If the BE is based on an
exposure guidance value derived for chronic exposures, then
interpretation of the tails of the distributions should be interpreted
with caution.
The calculated HQ values for persistent environmental chem-
icals are presented as a function of age in Fig. 2. The biomonitoring
levels measured for these chemicals are expected to be stable, with
little intra-individual variability. Since available data from pools do
not provide information on the distribution of concentrations
expected in a given age or gender group (i.e, 95th percentile),
maximum values are provided as a means of screening the data at
the upper range.
Cancer risk levels corresponding to population percentiles are
presented in Fig. 3 for biomarkers of inorganic arsenic, DDT, and
HCB. The frequency of detections for these biomarkers was all
above 60% in the CHMS.
4. Discussion
4.1. Cross-chemical evaluation
This evaluation across a range of selected biomarkers provides a
novel interpretation of the CHMS (2007–2011) biomonitoring data
in a risk-based context. The general pattern of these results
presented here is consistent with a similar evaluation previously
Table 2
Exposure guidance values, corresponding Biomonitoring Equivalents and biomonitoring data from the Canadian Health Measures Survey for biomarkers of environmental
chemicals with short elimination half-lives.
Chemical group,
CHMS cycle
Environmental chemical (biomarker,
if different)
Exposure guidance values
(type, reference)
BE and
matrix
Age group
(years)
n CHMS data (mg/L urine)
GMa(95% CI) 95th percentile
(95% CI)
Metals, 2009–2011 Arsenic, inorganic (sum of DMA,
MMA)
3E-04 mg/kg-d(TDI; Health
Canada, 2008a)
5.8 mg/L
urineb
6–79 2022 4.2(3.6, 4.8) 20c(11, 28)
Phthalates, 2009–
2011
Benzylbutyl phthalate (MBzP) 1.3 mg/kg-d(TDI; Health
Canada, 2000)
31,000 mg/
L urine
6–79 2037 7.5(6.6, 8.6) 57(48, 65)
Diethyl phthalate(MEP) 8E-01 mg/kg-d(RfD; U.S.
EPA, 1993)
18,000 mg/
L urine
6–79 2038 44(36, 54) –d
Di-n-butyl phthalate (MnBP) 6.3E-02 mg/kg-d(TDI;
Health Canada, 1994b)
1400 mg/L
urine
6–79 2033 20(18, 22) 87(74, 100)
Di-2(ethylhexyl) phthalate (sum of
MEHP, MEOHP, MEHHP)
4.4E-02 mg/kg-d(TDI;
Health Canada, 1994a)
610 mg/L
urine
6–79 2038 22(20, 24) 100(78, 120)
Environmental
Phenols,2009–
2011
Bisphenol A 2.5E-02 mg/kg-d(pTDI;
Health Canada, 2008b)
1000 mg/L
urine
6–79 2036 1.2(1.1, 1.3) 6.7(4.8, 8.5)
Triclosan 0.3 mg/kg-d(RfD; U.S. EPA,
2008)
6400 mg/L
urine
6–79 2027 15(12, 19) 710(540, 880)
Pesticides,2009–
2011
2,4-D 1E-03 mg/kg-d(RfD; U.S.
EPA, 2004)
200 mg/L
urine
6–79 2028 – 1.0(0.86, 1.2)
Deltamethrin (cis-DBCA) 1E-03 mg/kg-d(RfD; U.S.
EPA, 2010)
7 mg/L
urine
6–19 1016 0.01(0.01, 0.02) 0.20(0.13,
0.27)
1E-02 mg/kg-d(RfD; U.S.
EPA, 2010)
50 mg/L
urine
20–79 993 0.01(0.009, 0.01) 0.14c(0.050,
0.24)
Cyﬂuthrin (4-F-3-PBA) 2E-02 mg/kg-d(TDI; Health
Canada, 1992)
200 mg/L
urine
6–79 2022 – 0.11c(0.035,
0.18)
Abbreviations: BE, Biomonitoring Equivalent; CHMS, Canadian Health Measures Survey; CI, conﬁdence interval; 24-D, 2,4-dichlorophenoxyacetic acid; cis-DBCA, cis-3-(2,2-
dibromovinyl)-2,2-dimethylcyclopropane-1-carboxylic acid; DMA, dimethylarsinic acid; 4-F-3-PBA4-ﬂuoro-3-phenoxybenzoic acid; GM, geometric mean; HC, Health
Canada; MnBP, mono-n-butyl phthalate; MBzP, mono-benzyl phthalate; MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEHP, mono-2-ethylhexyl phthalate; MEOHP,
mono-(2-ethyl-5-oxohexyl) phthalate; MEP, mono-ethyl phthalate; MMA, monomethylarsonic acid; pTDI, provisional tolerable daily intake; RfD, reference dose;
TDItolerable daily intake.
a If >40% of samples were below the limit of detection, the GM was not calculated.bDMA + MMA only due to low detection rates for other inorganic arsenic species (arsenite
and arsenate).
cData are used with caution as coefﬁcient of variation is between 16.6% and 33.3%.
dData are considered too unreliable to be published as coefﬁcient of variation is greater than 33.3%.
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and Nutrition Examination Survey (NHANES; 2001–2010) (Ayl-
ward et al., 2013). For non-cancer effects, HQ values for the CHMS
data exceeded 1 at the 95th percentile for only two (inorganic
arsenic and cadmium) biomarkers of environmental chemicals or
groups of chemicals selected for this evaluation, suggesting most
chemical exposures in Canadians are below current exposure
guidance values. Similarly, for the NHANES data, of the substances
common to both analyses, HQ values at the 95th percentile
exceeded 1 for inorganic arsenic, dioxins/furans/DL-PCBs, cadmi-
um (in smokers) and DEHP (Aylward et al., 2013). As with the
CHMS analysis, all environmental chemicals included in NHANES
had HQ values below 1 at the geometric mean. These results
suggest both populations are likely exposed below the exposure
guidance value at the time of sampling. For DEHP, the differences in
HQ values between the CHMS analysis and that of the NHANES
data may be due to the use of a different BE value; the CHMS
analysis was based upon a Health Canada derived TDI and
considered only three metabolites while the NHANES analysis
was based upon an U.S. EPA derived RfD and considered four
metabolites (Aylward et al., 2009b, 2012). For dioxins/furans/DL-
PCBs, the CHMS analysis was based upon the maximum concen-
trations from pooled samples which are not comparable to the
upper bound 95th percentile of the distribution in the general
population used in the NHANES analysis.
For the majority of short-lived chemicals, the results of this
evaluation suggest that, in general, exposures to short-lived
compounds do not exceed current exposure guidance values.However, HQ values approached 1 at the geometric mean of the
sum of inorganic arsenic-derived urinary biomarkers, monome-
thylarsonic acid (MMA) and dimethylarsinic acid (DMA), suggest-
ing that exposures may be near the existing Health Canada
exposure guidance value based on non-cancer endpoints (Health
Canada, 2008a). The estimated cancer risks were also calculated
for the sum of MMA and DMA, based on Health Canada cancer
slope factor (Health Canada, 2006). Cancer risk level for the
geometric mean of these biomarkers exceeded 1 104, which is
slightly above the range deﬁned as essentially negligible (e.g.:
1 105–1 106) (Health Canada, 2010b). However, caution is
required when interpreting data for biomarkers of inorganic
arsenic, as the predominant metabolite, DMA, has shown
associations with organic arsenic species exposure. Aylward
et al. (2014) showed a strong correlation between DMA and
organic arsenic species in NHANES data, suggesting co-exposure or
even metabolism of the organic species to DMA. Hence, it seems
DMA when used as a biomarker of inorganic arsenic exposure may
overestimate the actual exposure. Thus, a more focused chemical-
speciﬁc analysis for inorganic arsenic including a detailed
examination of exposure data may be required to determine
whether current exposures are of concern.
The HQ values did not exceed 1 at the geometric mean for any of
the persistent chemicals. However, calculated HQ values for
cadmium exceed 1 at the 95th percentile of the smoking and
non-smoking population aged 40–59 and 60–79 years. In the case
of cadmium with a long biological half-life of 6–38 years in the
kidney, concentrations at the 95th percentile are considered
Table 3
Exposure guidance values, corresponding Biomonitoring Equivalents and biomonitoring data from the Canadian Health Measures Survey for biomarkers of persistent
environmental chemicals.
Environmental chemical
(biomarker, if different),
CHMS cycle
Exposure guidance
values
BE Units and
matrix
CHMS data
Sub-
population
Age group
(years)
n GMa(95% CI) 95th percentile (95% CI)
Cadmium, 2009–2011 RfD (U.S. EPA, 2004):
5E-04 mg/kg-d
1.5 mg/L urine Non-smokers 6–11 1052 0.25(0.21, 0.30) 0.87(0.64, 1.1)
12–19 944 0.27(0.22, 0.32) 0.81(0.68, 0.94)
20–39 1008 0.33(0.28, 0.39) 1.1(0.90, 1.3)
40–59 969 0.42(0.36, 0.49) 1.8(1.3, 2.3)
60–79 918 0.48(0.43, 0.53) 2.0(1.6, 2.4)
Smokers 6–11 NA NA NA
12–19 96 0.29(0.22, 0.38) 0.76(0.54, 0.98)
20–39 310 0.40(0.32, 0.50) 1.5b(0.91, 2.1)
40–59 258 0.97(0.83, 1.1) 3.2(2.4, 3.9)
60–79 166 1.1(0.80, 1.5) 4.1b(2.4, 5.7)
DDT (sum of DDT, DDE),
2007–2009
TDI (WHO, 2000):
0.01 mg/kg-d
40,000 ng/g Plasma
lipid
20–39 526 96(78, 120) –c
40–59 596 170(140, 210) 890b(430, 1400)
60–79 546 290(250, 350) 1600b(690, 2200)
Hexachlorobenzene,
2007–2009
TDI (Health Canada,
1996):
5E-04 mg/kg-d
250d ng/g Plasma
lipid
20–39 525 – 23b(10, 35)
40–59 596 9.7(8.5, 11) 25(22, 27)
60–79 545 13(11, 15) 36(23, 50)
PBDE 99, 2007–2009 RfD (U.S. EPA, 2008):
1E-04 mg/kg-d
520 ng/g Plasma
lipid
20–39 526 – 14(11, 17)
40–59 594 – 12b(8.5, 15)
60–79 545 – 14b(5.3, 22)
PCBs (based on sum of
PCB 138, 153, 180e), 2007–
2009
Concentrations of
concern (ANSES, 2010)
1800 ng/g Plasma
lipid
Males 20–39 240 34(28, 43) 130b(71, 190)
40–59 281 99(85, 120) –c
60–79 280 200(180, 230) 640(490, 790)
700 ng/g Plasma
lipid
Females 20–45 396 40(33, 49) 150(97, 200)
1800 ng/g Plasma
lipid
Females 46–59 204 110(99, 130) 330(240, 420)
60–79 265 170(150, 200) 460(350, 570)
Abbreviations: BE, Biomonitoring Equivalent; CHMS, Canadian Health Measures Survey; CI, conﬁdence interval; DDE, dichlorodiphenyldichloroethylene; DDT,
dichlorodiphenyltrichloroethane; GM, geometric mean; HC, Health Canada; PBDE, polybrominateddiphenyl ether; PCB, polychlorinated biphenyl; RfD, reference dose;
TDI, tolerable daily intake.
a If >40% of samples were below the limit of detection, the GM was not calculated.
bData are used with caution as coefﬁcient of variation is between 16.6% and 33.3%.
cData are considered too unreliable to be publishedas coefﬁcient of variation is greater than 33.3%.
dCalculated as per Aylward et al. (2010) using a more recent TDI (Health Canada, 1996).
eCalculated as 1.7 P(PCB 138, 153, 180), per conclusions in ANSES (2010).
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(Hays et al., 2008b). Based upon previous studies, urinary cadmium
levels were anticipated to be higher in smokers than non-smokers
(NTP, 2011; Riederer et al., 2012). However, cadmium HQ values
approached 1 at the 95th percentile even in non-smokers of older
age groups. Urinary cadmium levels are considered to be a highly
relevant biomarker for the critical dose metric of renal cortex
cadmium concentrations (Hays et al., 2008; Järup et al., 1998 Järup
et al.,1998). For these reasons, HQ values approaching or exceeding
1 for cadmium provide an indication that exposure levels may be
exceeding exposure guidance values, at least for a portion of the
population. Thus, a more focused chemical-speciﬁc analysis for
cadmium including a detailed examination of exposure data may
be required to determine whether current exposures are of
concern.4.2. Limitations of screening with Biomonitoring Equivalents
Calculated HQ values using BEs do not represent medical
diagnostic criteria and cannot be used to evaluate the likelihood
of an adverse health effect in an individual or among a population.
HQ values above 1 indicate exposures at or above the current
exposure guidance values which may lessen the safety margin,
but do not necessarily result in any signiﬁcant adverse health
effects. Therefore, similar to when other exposure guidance
values are exceeded; chemical-speciﬁc HQ values above 1 should
result in further investigation and can be used to determine
priorities for further efforts when multiple contaminants are
evaluated.
For a single substance, there may exist multiple BE values each
derived based upon exposure guidance values from different
Table 4
Exposure guidance values, corresponding Biomonitoring Equivalents and pooled biomonitoring data from the Canadian Health Measures Survey for biomarkers of persistent
environmental chemicals, hexabromocyclododecane and dioxins.
Environmental chemical, CHMS cycle
(biomarkers)
Exposure guidance values (type, reference) BE Units and
matrix
CHMS data
Age group
(years)
Pools: n Min.
value
GM Max.
value
Dioxin TEQ, 2007–2009(PCDD/F + DL-
PCB)
0.7 pg/kg-d(RfD; U.S. EPA, 2012a,b) –a 6–11 10: 880 2.0 5.8 9.3
15 pg/g serum
lipid
12–19 10: 893 3.9 5.2 8.4
21 pg/g serum
lipid
20–39 13: 1086 6.0 8.3 12
40–59 14: 1158 12 13 16
60–79 12: 1042 5.1 14b 25
HBCD, 2007–2009(
P
of a-, &beta;- and
g-HBCD)
10 mg/kg-d(NOAEL, Point of departure; Health
Canada, 2010a)
10000c ng/g serum
lipid
6–11 10: 880 0.51 –d 8.9
12–19 10: 893 0.50 –d 3.3
20–39 13: 1086 0.33 0.75 1.2
40–59 14: 1158 0.43 0.79 1.1
60–79 12: 1042 0.51 –d 3.8
Abbreviations: BE, Biomonitoring Equivalent; CHMS, Canadian Health Measures Survey; DL-PCB, dioxin-like polychlorinated biphenyls; GM, geometric mean;HBCD,
hexabromocyclododecane; HC, Health Canada; NOAEL, no observed adverse effect level; PCDD, polychlorinated dibenzodioxins; PCDF, polychlorinated dibenzofurans; RfD,
reference dose; TEQ, toxic equivalent.
a Appropriate BE values for children under the age of 12 have not yet been identiﬁed (Aylward et al., 2012).
b Data are used with caution as coefﬁcient of variation is between 16.6% and 33.3%.
cDerived as a provisional BE value based upon the point of departure from Health Canada risk assessment evaluations in the absence of an exposure guidance value.
dData are considered too unreliable to be publishedas coefﬁcient of variation is greater than 33.3%.
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is that regulatory exposure guidance values are reasonable and
protective. Since BEs are meant to assist in the interpretation of
human biomonitoring data within the context of the existing risk
assessment paradigm, the evaluation framework presented here
does not address any underlying limitations or uncertainties in
existing exposure guidance values.
This analysis is only evaluating one chemical at a time and not
considering the impacts of multiple chemical exposures. In many
traditional risk assessment, exposure guidance values apply to a
single substance, from a single route of exposure, and an associated
BE also represents a substance-speciﬁc level, without consider-
ation of aggregate or cumulative exposure. In this sense, the
approach presented here is consistent with the many current
practise in regulatory risk assessment at this time.
Screening values such as BEs need to be regarded as interim
values that can be updated as new data on toxicity become available,
or replaced if more robust values such as human epidemiology-
derived guidance values in blood or urine are adopted.Table 5
Cancer reference values, risk levels and corresponding Biomonitoring Equivalents ident
Measures Survey.
Environmental chemical (biomarker, if different) Cancer reference value
Arsenic (sum of MMA, DMA) Oral CSF (Health Canad
DDT (sum of DDT, DDE) Oral CSF (U.S. EPA, 1991
Hexachlorobenzene TD05 (Health Canada, 1
Abbreviations: BE, Biomonitoring Equivalent; CSF, cancer slope factor; DDE, dichlorodiph
acid; HC, Health Canada; MMA, monomethylarsonic acid; RSD,risk speciﬁc dose;TD, tuIn general, the urinary BE values were derived using assump-
tions regarding urinary ﬂow and excretion fraction for people ages
6 and above (Hays et al., 2010). Therefore in this evaluation, urinary
data for children under six were excluded due to the uncertainties
in extrapolation of the BE values for application to younger
children. As for plasma there are no existing data for children since
the survey population in the CHMS was limited to 20–79 years.
4.3. CHMS data gaps and limitations
Relevance of the various biomarkers to the critical effect varies
for the different chemicals considered here and this is reﬂected in
the measures of relevance in Table 1 In fact, some biomarkers are
highly relevant while other are only moderately relevant for the
critical dose metric (Hays et al., 2008a). Most biomarkers analysed
in this manuscript were considered to have medium to high
relevance. Biomarkers for inorganic arsenic however were
considered to be of low relevance to the critical dose metric
(Hays et al., 2010).iﬁed for biomarkers of environmental chemicals measured in the Canadian Health
 Risk level BERSD
a, 2006):1.8 (mg/kg-d)1 104 1.1 mg/L urine
105 0.11 mg/L urine
106 0.011 mg/L urine
):0.34 (mg/kg-d)1 104 4000 ng/g plasma lipid
105 400 ng/g plasma lipid
106 40 ng/g plasma lipid
996):0.06 mg/kg-d 104 1500 ng/g plasma lipid
105 150 ng/g plasma lipid
106 15 ng/g plasma lipid
enyldichloroethylene; DDT, dichlorodiphenyltrichloroethane; DMA, dimethylarsinic
morigenic dose.
Fig. 2. Hazard quotients (HQ) for persistent environmental chemicals based upon biomonitoring data from the Canadian Health Measures Survey (CHMS), as a function of age
group, and existing Biomonitoring Equivalents for the relevant biomarkers of exposure.Biomonitoring Equivalents and CHMS data are reported in Table 3 and 4. Squares (&)
represent HQ values at the geometric mean and diamonds (^) represent HQ values at the 95th percentile. For the pooled CHMS population data, HQ values at the geometric
mean are represented by small squares ( ) with error bars presenting the HQ values at the maximum and minimum data points. The absence of markers indicates that the
either the estimate was too unreliable to be reported or that the geometric mean was not calculated as >40% of samples were below the limit of detection.
Abbreviations: DDT, dichlorodiphenyltrichloroethane; HBCD, hexabromocyclododecane; HCB, hexachlorobenzene; PBDE, polybrominateddiphenyl ether; PCBs,
polychlorinated biphenyls; TEQ, toxic equivalent.
Fig. 1. Hazard quotients (HQ) for environmental chemicals with short elimination half-lives based upon biomonitoring data from the Canadian Health Measures Survey
(CHMS) and existing Biomonitoring Equivalents for the relevant biomarkers of exposure. Biomonitoring Equivalents and CHMS data are reported in Table 2. Squares (&)
represent HQ values at the geometric mean of the CHMS population data and diamonds (^) represent HQ values at the 95th percentile. The absence of a marker indicates that
the geometric mean was not calculated as >40% of samples were below the limit of detection.
Abbreviations: BBP, benzyl butyl phthalate; BPA, bisphenol A; 2,4-D, 2,4-dichlorophenoxyacetic acid; DnBP, di-n-butyl phthalate; DEHP, di-2(ethylhexylphthalate); DEP,
diethyl phthalate.
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Fig. 3. Box plots showing cancer risk for biomarkers of urinary inorganic arsenic
(DMA + MMA), DDT and HCB from the Canadian Health Measures Survey based on
cancer exposure guidance values from Health Canada and U.S. EPA (see Table 5).
Medians are represented by the horizontal lines; boxes extend to the 25th and 75th
percentiles, and whiskers extend to the 5th and 95th percentiles.
Abbreviations: DDT, dichlorodiphenyltrichloroethane; DMA, dimethylarsinic acid;
HCB, hexachlorobenzene; MMA, monomethylarsonicacid.
A. St-Amand et al. / Toxicology Letters 231 (2014) 126–134 133The sampled medium may have been chosen on the basis of ease
of collection rather than ease of interpretation in the toxic
responses. For example, total BPA (free plus conjugated) is measured
in urine, although free BPA in blood would be a more relevant
biomarker for the target organ (Krishnan et al., 2010). The more
distant the sampled medium and measured biomarker is from the
target organ, the more uncertainty may exist in the interpretation of
the data in a risk-based context. Other times, the target organ or
system is unknown, because the mode of action is not fully
understood, as in the case of biomarkers of inorganic arsenic.
5. Conclusions
The biomonitoring component of the CHMS provides a
snapshot of population exposure integrated from all sources and
when coupled with BE values, it offers a unique opportunity to
screen population and prioritize environmental chemicals based
on exposure. The results have the potential to be used by
researchers, risk assessors, and risk managers.
The CHMS biomonitoring program includes future cycles in
which additional analytes will be added or rotated in. Future work
in the interpretation of biomonitoring data may include evaluation
of combined chemical exposures with anticipated common
toxicity endpoints or mode of action (Aylward et al., 2013; Meek
et al., 2011). Derivation of additional BEs would increase the
usability of this approach.
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